Australia’s psychedelic medicine industry has crossed the regulatory threshold. Since 1 July 2023, specifically authorised psychiatrists have been able to prescribe MDMA for post-traumatic stress disorder and psilocybin for treatment-resistant depression under the Therapeutic Goods Administration’s Authorised Prescriber framework. The medicines remain unapproved therapeutic goods and access is tightly controlled. But psychedelic-assisted psychotherapy is now […]
Already subscribed? Log in
US-listed BioAdaptives, Inc. (OTCID: BDPT) has signed a definitive agreement to acquire Xycota Biosciences LLC, a privately held biotechnology company developing experimental psychedelic medicines for psychiatric and neurological...
Canadian biotechnology company PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) has signed an agreement with Corealis Pharma Inc., a contract development and manufacturing organisation based in Laval,...
Definium Therapeutics (NASDAQ: DFTX) is set to present findings from three positive Phase 3 clinical trials of its LSD-based drug candidate, DT120 ODT, at the 2026 Neuroscience Education...
New preclinical findings suggest EB-003 can alter brain activity without producing some of the adverse neurological effects observed with DMT in mice. Enveric Biosciences (NASDAQ: ENVB) has reported...
Psychedelics.media delivers trusted news, intelligence, and insights for the global psychedelic medicine industry.
